| content | |||||||||||||||||||||||||||||||||||||||||||||||
 |
|
|
Ethionamide
|
|
| Systematic (IUPAC) name | |
| 2-ethylpyridine-4-carbothioamide | |
| Identifiers | |
| CAS number | |
| ATC code | J04 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C8H10N2S |
| Mol. mass | 166.244 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | Approximately 30% bound to proteins. |
| Metabolism | ? |
| Half life | 2 to 3 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Ethionamide (2-ethylthioisonicotinamide, Trecator SC) is an antibiotic used in the treatment of tuberculosis.
It has been proposed for use in combination with gatifloxacin.[2]
The action may be through disruption of mycolic acid.[3]
References
- ^ Vannelli TA, Dykman A, Ortiz de Montellano PR (April 2002). "The antituberculosis drug ethionamide is activated by a flavoprotein monooxygenase". J. Biol. Chem. 277 (15): 12824–9. doi:. PMID 11823459.
- ^ Cynamon MH, Sklaney M (August 2003). "Gatifloxacin and ethionamide as the foundation for therapy of tuberculosis". Antimicrob. Agents Chemother. 47 (8): 2442–4. PMID 12878502. PMC:166105.
- ^ Quémard A, Lanéelle G, Lacave C (June 1992). "Mycolic acid synthesis: a target for ethionamide in mycobacteria?". Antimicrob. Agents Chemother. 36 (6): 1316–21. PMID 1416831. PMC:190338.
 |
This antibiotic-related article is a stub. You can help Wikipedia by expanding it. |
